tldrdailynews.com logo

Novo Nordisk Acquires Cardior for $1.1 Billion to Expand Cardiovascular Portfolio

1 min read
Source: Endpoints News
Novo Nordisk Acquires Cardior for $1.1 Billion to Expand Cardiovascular Portfolio
Photo: Endpoints News
TL;DR

Novo Nordisk is set to acquire German biotech Cardior Pharmaceuticals, a Phase 2 RNA startup, for up to $1.1 billion in a move to strengthen its presence in cardiovascular disease, following the recent label expansion of its obesity drug We­govy to include the reduction of cardiovascular events. This acquisition marks a strategic shift for Novo, which had previously focused on obesity-related acquisitions.

Topics:businessbusiness-and-pharmaceuticals#acquisition#business-and-pharmaceuticals#cardior-pharmaceuticals#cardiovascular-disease#novo-nordisk#rna-startup
Share this article
  1. Novo to buy mid-stage heart failure biotech Cardior for up to $1.1B  Endpoints News
  2. Novo Nordisk Boosts Cardiovascular Pipeline With $1.1 Billion Purchase of Cardior Pharmaceuticals  The Wall Street Journal
  3. Novo Nordisk strikes deal worth up to $1.1 bln to expand cardio business  Reuters
  4. Novo Nordisk targets heart disease in $1.1 billion deal  MarketWatch
  5. Novo Nordisk inks $1B buyout to pump up heart failure plans  Fierce Biotech

Want the full story? Read the original reporting

Read on Endpoints News